
Austria · Education management startup
Viora is a medical aesthetics company founded in 2005, specializing in advanced, non-invasive devices for skin treatments and aesthetic procedures.
Funding reportedLast round: Angel
Viora is a medical aesthetics company founded in 2005, specializing in advanced, non-invasive devices for skin treatments and aesthetic procedures.
Headquartered in New York, Viora has established itself as a leading manufacturer of energy-based devices, utilizing technologies such as laser, IPL, proprietary radiofrequency, microdermabrasion, and electro-mesotherapy. The company serves a diverse clientele, including aesthetic practitioners, dermatologists, cosmetic and plastic surgeons, general practitioners, dentists, and medical spa owners. Viora's product portfolio features multi-technology platforms like the V-series, the advanced radiofrequency system ReactionTM, the PristineTM microdermabrasion device, and the Infusion system. These devices are designed for various aesthetic treatments, including skin rejuvenation, hair removal, and body contouring. With a global reach, Viora operates directly in the US and through a distribution network in over 60 countries, supporting more than 10,000 customers worldwide. The company emphasizes clinical training, technical support, and practice development to enhance the capabilities of its users.
Funding, as reported
What they build
Known for
gender equalitygender balance metricswomen empowermentpersonal brandingeducationhr technologyinformation technology & serviceswomen in managementmicrolearning marketdigital mentoringfemale talent retentione-learningimpact measurementkarriereentwicklungdiversity & inclusionwork-life balance
Built with from their website
Contact Form 7Google Tag ManagerAmazon CloudFrontWordPress.orgHREF LangFont AwesomeYouTubeGoogle WorkspaceCloudFlareViewport Meta
Google PlaySite KitDocSendWPMU DEV SmushHubspotQuantcastGoogle MeetWeglot
Add your raise, your deck and your story, and put Viora - visible through confidence in front of investors. Or tell us what we have wrong.